Hemostemix Inc (OTC:HMTXF) Financings

Hemostemix Inc

Financings

RaiseDateIn US dollars
Private placement of units
Tranche closed: C$380,500 in the latest tranche · C$0.05 a unit · ½ warrant at C$0.12 for 24 months
Use of proceeds: ACP-01 manufacturing, clinical-program preparation, regulatory submissions, physician education and general working capital
Oct 7, 2026
Private placement of units
Tranche closed: C$360,000 raised · C$0.05 a unit · ½ warrant at C$0.12 for 24 months
Insiders: Certain directors of the Company participated, directly and indirectly, in the Offering
Use of proceeds: Sales, marketing, patient acquisition and commercialization; ACP-01 production; Bahamas regulatory fees; working capital
Jun 26, 2026
Private placement of units
Announced: up to C$1M · C$0.05 a unit · ½ warrant at C$0.12 for 24 months
Insiders: Certain directors of the Company may participate in the private placement, a related party transaction under MI 61-101
Use of proceeds: Sales, marketing, patient acquisition, physician education, commercialization, ACP-01 production, Bahamas regulatory fees and working capital
Jun 17, 2026US$712,555
Private placement of common shares
Closed: C$480,000 raised · C$0.12 a share
Use of proceeds: General working capital, including regulatory, clinical and commercialization work on ACP-01 (VesCell)
Dec 31, 2025US$350,212
Private placement of units
Closed: C$518,440 raised · C$0.11 a unit · 1 warrant at C$0.15 for 24 months
Buyers: Director of the Company (participating in the Offering)
Insiders: Certain directors participated directly and indirectly
Use of proceeds: General working capital and ongoing operations, including marketing and sales of VesCell
Dec 2, 2025
Private placement of common shares
Closed: C$280,594 raised · C$0.125 a share
Insiders: The investor is arm's length and not a Related Party to the Company.
Use of proceeds: General working capital, ongoing operating expenses and business development.
Nov 18, 2025US$200,467
Therapy Convertible Debenture
Tranche closed: US$1.14M raised
Use of proceeds: General working capital, corporate overhead and research and development activities
Aug 20, 2025
Private placement of units
Closed: C$2.97M raised · C$0.1 a unit · 1 warrant at C$0.15 for 24 months
Buyers: Peter Lacey (subscribed for $1,500,000); Loran Swanberg (subscribed for $100,000); Mr. Lacey (subscribed to 15,000,000 Units; now owns 24,316,937 Common Shares (13.40% non-diluted))
Insiders: Directors Peter Lacey and Loran Swanberg directly and indirectly participated; related party transaction under MI 61-101
Use of proceeds: Repay CD#1 in full at a 50% discount ($1,250,000) and general working capital, including marketing and sales of VesCell
Jul 31, 2025US$2.18M
Private placement of common shares
Closed: C$469,366 raised · C$0.12 a share
Insiders: The investor is arm's length to the Company and is not a Related Party
Use of proceeds: General working capital, operational expenses and business development
Jul 4, 2025US$345,046
Private placement of common shares
Closed: US$336,500 raised · C$0.295 a share
Buyers: CytoImmune (USD $336,500 for 1,634,466 Common Shares); CytoImmune Therapeutics LLC (1,634,466 Common Shares at CAD $0.295 each)
Use of proceeds: General working capital, including business development activities
May 12, 2025
Private placement of units
Closed: C$2.73M raised · C$0.05 a unit · 1 warrant at C$0.12 for 24 months
Insiders: Certain directors of the Company participated in the Offering, a related party transaction under MI 61-101
Use of proceeds: Advance stem cell therapeutics platform, initiate sales and process initial ACP batches, pay fees, and general working capital
Dec 3, 2024

Read by 6ix AI from the company's releases

Hemostemix Inc (OTC:HMTXF) Financings | 6ix